Celgene

Equities

CELG

Delayed Nasdaq Other stock markets 21:00:00 20/11/2019 GMT			5-day change	1st Jan Change
108.2 ^USD	+0.10%		-1.97%	+68.89%

2023	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
2021	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI

Tranche Update on Celgene Corporation's Equity Buyback Plan announced on June 12, 2013.

January 26, 2017 at 12:36 pm

From October 1, 2016 to December 31, 2016, the company has repurchased 1,351,779 shares, representing 0.17% for $133.54 million. With this, the company has completed the repurchase of 94,201,600 shares, representing 11.75% for $9,268.97 million under the buyback announced on June 12, 2013.

Latest news about Celgene

Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	14/06/23	CI
Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	08/09/21	CI
Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity	22/06/21	CI
Celgene Corporation Issues Notice of Redemption of Notes	22/02/21	CI
Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion	04/02/21	CI
Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors	04/01/21	CI
Amgen : Signs Licensing Agreement With Medicines Development for Global Health	22/12/20	MT
Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook	05/11/20	MT
Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors	22/09/20	CI
Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors	21/09/20	CI
Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene	25/03/20	CI
Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors	10/03/20	CI
Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis	04/03/20	CI
DISH Network : Democratic lawmaker presses antitrust enforcers on company ties, settlements	08/01/20	RE
Galecto, Inc. acquired PharmAkea, Inc. from Bay City Capital LLC and Celgene Corporation for $17.4 million	06/01/20	CI
GNS Healthcare, Inc. announced that it has received $28 million in funding from Cigna Ventures, Amgen Ventures, Celgene Corporation, Echo Health Ventures, Alexandria Venture Investments, LLC, Merck Global Health Innovation Fund, LLC, and another investor	06/01/20	CI
More drugmakers hike U.S. prices as new year begins	01/01/20	RE
Dealmakers eye cross-border M&A recovery as mega mergers roll on	31/12/19	RE
Oncorus, Inc. announced that it has received $89.6 million in funding from a group of investors	19/12/19	CI
Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug	21/11/19	RE
Celgene Corporation(NasdaqGM:CELG) dropped from S&P 500 Growth	21/11/19	CI
Celgene Corporation(NasdaqGM:CELG) dropped from S&P TMI Index	21/11/19	CI
Celgene Corporation(NasdaqGM:CELG) dropped from INDUSTRIALS	21/11/19	CI
Celgene Corporation(NasdaqGM:CELG) dropped from S&P 500 Value	21/11/19	CI
Celgene Corporation(NasdaqGM:CELG) dropped from S&P Global 1200	21/11/19	CI

Chart Celgene

Duration

Period

More charts

Company Profile

Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).

Sector

More about the company